- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 182
Cyteir cites $80m series C investors
Osage University Partners has contributed to an oversubscribed series C round for Cyteir, which was led by RA Capital.
Feb 12, 2021Insightin inspires with $12m series A
The healthcare engagement technology provider has received $12m in a round co-led by the Blue Cross Blue Shield-backed Blue Venture Fund.
Feb 12, 2021Saykara attracts Nuance in acquisition deal
The medical documentation tool developer has been acquired by Nuance Communications having raised $7.5m from investors including NewYork-Presbyterian.
Feb 12, 2021Phable tells of $12m series A
Phable, developer of a chronic disease assistance app, has secured funding in a round led by healthcare provider Manipal Hospitals.
Feb 12, 2021Day One progresses to $130m series B
Access Biotechnology returned for a round that will push Day One Biopharmaceuticals' paediatric drug candidate through a phase 2 study.
Feb 11, 2021Daily deal net: February 11, 2021
Today's deal net contains news from PGDx, Notch Therapeutics, Quell Therapeutics, SpyBiotech, Vision Medicals, Future Meat Technologies, BusUp and Advanced Chemotherapy Technologies.
Feb 11, 2021RapidSOS rescues $85m in series C round
The AAA, CSAA, Microsoft and Motorola Solutions-backed emergency response software developer’s latest round, led by Insight Partners, brought its total funding to $200m.
Feb 11, 2021PGDx picks up $103m in series C
The round brought the total raised by the oncology diagnostics technology developer, backed by Bristol Myers Squibb, Helsinn and Inova Health, to $244m.
Feb 11, 2021Notch marks $85m series A round
Existing strategic investor Allogene Therapeutics has taken part in an $85m series A round for Notch Therapeutics, which is working on cancer treatments.
Feb 11, 2021Drug Farm harvests $56m
The WuXi AppTec-backed round will help the hepatitis B drug developer begin human trials for its lead drug candidate.
Feb 11, 2021About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


